PF-06939926 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 8 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05429372 (ClinicalTrials.gov) | August 8, 2022 | 8/10/2021 | Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy | A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHY | Muscular Dystrophy, Duchenne | Genetic: PF-06939926 | Pfizer | NULL | Recruiting | 2 Years | 3 Years | Male | 10 | Phase 2 | United States;Australia |
| 2 | EUCTR2019-002921-31-BE (EUCTR) | 18/06/2021 | 07/09/2020 | Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DUCHENNE MUSCULAR DYSTROPHY (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: PF-06939926 Product Code: PF-06939926 INN or Proposed INN: PF-06939926 Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 99 | Phase 3 | United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of | ||
| 3 | EUCTR2019-002921-31-FR (EUCTR) | 15/03/2021 | 07/09/2020 | Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DUCHENNE MUSCULAR DYSTROPHY (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: PF-06939926 Product Code: PF-06939926 INN or Proposed INN: PF-06939926 Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 99 | Phase 3 | United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of | ||
| 4 | EUCTR2019-002921-31-IT (EUCTR) | 04/12/2020 | 06/11/2020 | Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - - | DUCHENNE MUSCULAR DYSTROPHY (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: PF-06939926 Product Code: [PF-06939926] INN or Proposed INN: PF-06939926 | PFIZER INC | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 99 | Phase 3 | United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of | ||
| 5 | NCT04281485 (ClinicalTrials.gov) | November 5, 2020 | 11/2/2020 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Duchenne Muscular Dystrophy | Genetic: PF-06939926;Other: Placebo | Pfizer | NULL | Recruiting | 4 Years | 7 Years | Male | 99 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom |
| 6 | EUCTR2019-002921-31-GB (EUCTR) | 29/09/2020 | 02/07/2020 | Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DUCHENNE MUSCULAR DYSTROPHY (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: PF-06939926 Product Code: PF-06939926 INN or Proposed INN: PF-06939926 Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 99 | Phase 3 | United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of | ||
| 7 | NCT03362502 (ClinicalTrials.gov) | January 23, 2018 | 29/11/2017 | A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy | A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | Duchenne Muscular Dystrophy | Genetic: PF-06939926 | Pfizer | NULL | Active, not recruiting | 4 Years | N/A | Male | 23 | Phase 1 | United States |
| 8 | EUCTR2019-002921-31-DE (EUCTR) | 28/07/2020 | Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DUCHENNE MUSCULAR DYSTROPHY (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: PF-06939926 Product Code: PF-06939926 INN or Proposed INN: PF-06939926 Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | Pfizer Inc. | NULL | NA | Female: no Male: yes | 99 | Phase 3 | United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of |